Heart Wall Articles & Analysis
14 news found
It was another first for EchoPixel when its Holographic Therapy Guidance (HTG) was used in a congenital heart surgery at Cincinnati Children’s Hospital Medical Center. ...
SQuEEZ is based on the ability in high resolution cardiac CT scans to track points on the endocardium as they move during the contraction of the heart to allow quantitative assessment of regional myocardial heart wall motion. The analysis of four dimensional SQuEEZ parameters has the potential to improve the ability to quantify accurately the ...
– July 12, 2022 – Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today announced that the U.S. ...
Specifically, the exquisite algorithms developed through machine learning characterize tissue types in the artery wall known to cause heart attacks, such as lipid rich necrotic core. ...
ByElucid
Only a physician can diagnose an arrhythmia. Heart Rhythm 2022 presentation time and location: Title: Forward-solution Computational Arrhythmia Source Mapping: The vMap Study Presented by Dr. ...
The wash is also compatible with all common implants and during clinical trial showed no irritation to key areas of the body including the skull (dura mater), heart, lungs, and chest wall articular cartilage of the body. Commenting on the agreement, Managing Director Judith Mitchell said: “We are delighted to expand our commercial footprint through the ...
The patent filing also covers a simplified design for deploying and retrieving the impeller and aortic stent components of the circulatory assist pump. Second Heart Assist, Inc. Second Heart Assist, Inc. is focused on the development of two models of percutaneously placed aortic stent-based circulatory assist pumps primarily for use in cardio-renal syndrome ...
– June 30, 2020 – Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced U.S. ...
WALTHAM. Mass.. May 19,2020 - Thermedicak a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT): today announced that it has received Breakthrough Device Designation from the U.S. Food & Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate® catheter. The FDA Breakthrough Devices Program is intended to help ...
– February 3, 2020 – Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced that the U.S. ...
CardioWise, Inc., is pleased to announce two significant patents protecting its heart function analysis software, Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ). ...
The design of conventional temporary pacing leads can cause serious complications, including perforation of the heart wall, which may lead to potentially life-threatening compression of the heart. Additionally, conventional leads can easily dislodge from the heart, often resulting in loss of pacing with serious consequences for ...
The design of conventional temporary pacing leads can cause serious complications, including perforation of the heart wall, which may lead to potentially life-threatening compression of the heart. Additionally, conventional leads can easily dislodge from the heart, often resulting in loss of pacing with serious consequences for ...
The SQuEEZ technology is based on the ability to track the heart wall as it moves during the contraction of the heart to allow quantitative assessment of regional heart wall motion from cardiac CT data. The analysis can accurately quantify the regional heart wall motion of the ...